CIK 0000882796 · Large accelerated filer
BIOCRYST PHARMACEUTICALS INC
Sign in to watch- Ticker
- BCRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 621413174
- Phone
- 919-859-1302
- Business address
- 4505 EMPEROR BOULEVARD, SUITE 200, DURHAM, NC, 27703
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-05-11 | Barnes Alane P Chief Legal Officer | Option exercise · Emp. Stock Option (Right to Buy) | −1,648 | 35,852 | ||
| 2021-05-11 | Barnes Alane P Chief Legal Officer | Option exercise · Emp. Stock Option (Right to Buy) | −33,132 | 0 | ||
| 2021-05-11 | Barnes Alane P Chief Legal Officer | Option exercise · Emp. Stock Option (Right to Buy) | −68,000 | 0 | ||
| 2021-05-10 | ABERCROMBIE GEORGE B Director | Sale | −7,000 | $12.70 | $89K | 3,000 |
| 2021-03-31 | Thackray Helen M. Chief R&D Officer | Grant or award | +100,000 | 100,000 | ||
| 2021-03-31 | Thackray Helen M. Chief R&D Officer | Grant or award · Emp. Stock Option (Right to Buy) | +400,000 | 400,000 | ||
| 2021-03-18 | Jones Michael L Exec. Director, Finance - PAO | Option exercise | +4,500 | $3.51 | $16K | 5,348 |
| 2021-03-18 | Jones Michael L Exec. Director, Finance - PAO | Option exercise · Emp. Stock Option (Right to Buy) | −4,500 | 0 | ||
| 2021-02-26 | INGRAM ROBERT ALEXANDER Director | Grant or award | +1,739 | $10.78 | $19K | 75,013 |
| 2021-02-26 | Hutson Nancy J Director | Grant or award | +463 | $10.78 | $5K | 64,756 |
| 2021-02-26 | HEGGIE THERESA Director | Grant or award | +463 | $10.78 | $5K | 13,849 |
| 2021-02-26 | ASELAGE STEVE Director | Grant or award | +927 | $10.78 | $10K | 31,496 |
| 2021-02-22 | Sheridan William P Senior VP - CMO | Option exercise | +41,250 | $4.15 | $171K | 52,725 |
| 2021-02-22 | Sheridan William P Senior VP - CMO | Sale | −41,250 | $11.57 | $477K | 11,475 |
| 2021-02-22 | Sheridan William P Senior VP - CMO | Option exercise · Stock Option (Right to Buy) | −41,250 | 0 | ||
| 2021-02-19 | Babu Yarlagadda S Senior VP - Drug Discovery | Option exercise | +50,000 | $4.15 | $208K | 205,587 |
| 2021-02-19 | Babu Yarlagadda S Senior VP - Drug Discovery | Shares withheld for taxes | −22,431 | $11.53 | $259K | 183,156 |
| 2021-02-19 | Babu Yarlagadda S Senior VP - Drug Discovery | Option exercise · Stock Option (Right to Buy) | −50,000 | 0 | ||
| 2020-12-15 | Sniecinski Megan Chief Business Officer | Grant or award · Emp. Stock Option (Right to Buy) | +225,000 | 225,000 | ||
| 2020-12-15 | Jones Michael L Exec. Director, Finance - PAO | Grant or award · Emp. Stock Option (Right to Buy) | +30,000 | 30,000 |
Page 23 of 27 · 522 trades